Aegerion Pharmaceuticals Company Profile (NASDAQ:AEGR)

Analyst Ratings

Consensus Ratings for Aegerion Pharmaceuticals (NASDAQ:AEGR) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $14.83 (930.09% upside)

Analysts' Ratings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Show:
DateFirmActionRatingPrice TargetActions
5/17/2016Leerink SwannBoost Price TargetOutperform$6.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/12/2016Bank of America Corp.DowngradeNeutral -> Underperform$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/21/2015GuggenheimUpgradeSell -> Buy$7.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015JPMorgan Chase & Co.Reiterated RatingNeutral$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Jefferies GroupLower Price TargetBuy$26.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2015Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/31/2014Deutsche Bank AGDowngradeBuy -> Hold$58.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/16/2016Q1($0.58)($1.72)$43.00 million$35.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q4($0.89)($0.69)$47.74 million$49.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.42)($0.34)$59.72 million$67.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q2($0.28)$0.23$58.98 million$64.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2015Q414($0.26)$0.06$59.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q4$0.08$0.11$49.18 million$51.71 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314($0.14)($0.20)$48.60 million$43.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2014Q214($0.41)($0.33)$35.40 million$36.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q1($0.35)($0.25)$33.58 million$27.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2014Q413($0.30)($0.14)$24.51 million$24.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2013Q313($0.50)($0.43)$13.07 million$16.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2013Q2 2013($0.62)($0.66)$4.27 million$6.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.56)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aegerion Pharmaceuticals (NASDAQ:AEGR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.77)$0.09($0.34)
Q2 20163($0.73)($0.01)($0.44)
Q3 20163($0.73)$0.15($0.37)
Q4 20163($0.78)($0.04)($0.42)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aegerion Pharmaceuticals (NASDAQ:AEGR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
8/19/2014Mark J FitzpatrickCFOBuy1,150$30.64$35,236.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2014Marc D BeerCEOBuy10,000$33.65$336,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014Marc D BeerCEOBuy10,000$30.12$301,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Marc D BeerCEOBuy10,000$31.59$315,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2014Marc BeerCEOBuy10,000$30.53$305,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Anne VanlentDirectorBuy4,000$33.78$135,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Marc BeerCEOBuy30,000$35.31$1,059,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/30/2014Craig FraserInsiderSell2,250$43.55$97,987.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/31/2014Craig FraserInsiderSell2,250$46.20$103,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Mark SumerayInsiderSell2,000$51.34$102,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014Craig FraserInsiderSell2,250$67.00$150,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2013Mark SumerayInsiderSell2,000$66.34$132,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/30/2013Marc D BeerCEOSell40,000$87.79$3,511,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2013Sandford D SmithDirectorSell2,502$95.00$237,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2013Mark SumerayInsiderSell2,000$80.33$160,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2013Mark SumerayInsiderSell3,500$93.17$326,095.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Mark SumerayInsiderSell2,000$89.77$179,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2013Perceptive Advisors LlcMajor ShareholderSell750,000$89.20$66,900,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2013David ScheerDirectorSell20,000$84.58$1,691,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Mark SumerayInsiderSell2,000$88.71$177,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2013Marc BeerCEOSell60,000$88.54$5,312,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Mark FitzpatrickCFOSell7,500$93.44$700,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Sandford SmithDirectorSell10,000$92.32$923,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2013Mark SumerayInsiderSell2,000$78.77$157,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2013Mark SumerayInsiderSell6,000$65.27$391,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Mark SumerayInsiderSell6,000$47.32$283,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.79$1,389,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/18/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$27.62$1,381,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/17/2013Perceptive Advisors LlcMajor ShareholderBuy50,000$26.73$1,336,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2013Perceptive Advisors LlcMajor ShareholderBuy475,000$27.07$12,858,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2012Perceptive Advisors LlcMajor ShareholderBuy20,000$21.27$425,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/29/2012Perceptive Advisors LlcMajor ShareholderBuy30,000$22.71$681,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/28/2012Perceptive Advisors LlcMajor ShareholderBuy150,000$21.25$3,187,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aegerion Pharmaceuticals (NASDAQ:AEGR)
DateHeadline
07/30/16 02:25 PMAegerion Pharmaceuticals Inc. (AEGR) Drops 5.16% on July 28 ... - Equities.com
07/28/16 10:57 AMAegerion Pharmaceuticals Inc. (AEGR) Jumps 7.64% on July 27 - Equities.com
07/23/16 02:20 PMEquity Roundup: Stock Performance Focus on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Press Telegraph
07/23/16 02:20 PMStock Displaying Signs of a Downtrend: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Press Telegraph
07/23/16 02:20 PMIs $2 Price Target Attainable For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)? - Investor Newswire
07/22/16 02:19 PMAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Decreased -2.61%: Ligand Pharmaceuticals Incorporated (NASDAQ ... - KC Register
07/21/16 02:20 PMAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 02:20 PMAegerion Pharma (AEGR) to Reduce Workforce as Part of Cost Reduction Plans - StreetInsider.com
07/20/16 03:09 PMAEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Costs Associated with -
07/20/16 03:04 PM4:04 pm Aegerion Pharma intends to withdraw lomitapide from the EU; is reducing ~13% of its global workforce -
07/20/16 03:02 PMAegerion Pharmaceuticals Announces Cost Reduction Plans - [GlobeNewswire] - CAMBRIDGE, Mass., July 20, 2016-- Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare ...
07/19/16 02:20 PMHow Analysts Rated Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Last Week? - Consumer Eagle
07/18/16 02:19 PMInvestor Watch: Volatility Recap on Shares of: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Engelwood Daily
07/18/16 07:06 AMHC Stocks Momentum: StemCells Inc (NASDAQ:STEM), Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - share market updates (press release)
07/18/16 07:06 AMAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Wall Street Analyst Recommendation Outlook - TGP
07/17/16 07:06 AMShares Moving Down on the Week: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Engelwood Daily
07/17/16 07:06 AMStrong Sell Calls For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) At 0 - Investor Newswire
07/16/16 02:20 PMAegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Sellers Covered 4.56% of Their Shorts - Consumer Eagle
07/14/16 02:21 PMEye on Stock Volatility for: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Engelwood Daily
07/13/16 02:19 PMAegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Short Interest Decreased By 4.56% - Consumer Eagle
07/12/16 02:23 PMBest Stocks: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Boston Scientific Corporation (NYSE:BSX), Retrophin ... - KC Register
07/10/16 02:19 PMEarnings Surprise in Focus: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Investor Newswire
07/10/16 07:05 AMAegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Sellers Covered 4.56% of Their Shorts - Press Telegraph
07/10/16 07:05 AMIs $2 Within Reach For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)? - Investor Newswire
07/08/16 02:21 PMAegerion Pharmaceuticals Inc. (AEGR) Jumps 7.14% on July 07 - Equities.com
07/07/16 02:21 PMHeightened Volatility Check on: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Engelwood Daily
07/06/16 02:21 PMIncreased Volatility Watch for: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Engelwood Daily
07/06/16 07:07 AMAegerion Pharmaceuticals Inc. (AEGR) Jumps 6.04% on July 04 - Equities.com
07/05/16 03:03 PMAEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
07/04/16 02:18 PMAegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Sellers Covered 4.56% of Their Shorts - Engelwood Daily
07/04/16 07:06 AMWere Analysts Bearish Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) This Week? - Press Telegraph
07/04/16 07:06 AMAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Broker Price Targets For The Coming Week - Fiscal Standard
07/02/16 02:18 PMAegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Expected to Reach Highs Of $6 - Investor Newswire
07/01/16 07:35 PMAegerion Pharmaceuticals Inc. (AEGR) Jumps 6.04% on July 01 - Equities.com
07/01/16 02:21 PMShares Headed Up in Session: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Telanagana Press
07/01/16 10:19 AMNew Broker Ratings For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - FTSE News
06/30/16 02:21 PMUpdate on Stock Volatility for: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Engelwood Daily
06/28/16 02:33 PMCovering the Bases on Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR): Where is the Stock Going? - Press Telegraph
06/27/16 07:05 AMWere Analysts Bearish Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) This Week? - Engelwood Daily
06/25/16 02:20 PMAegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Shorts Decreased by 4.56% After Short Covering - Engelwood Daily
06/25/16 02:20 PMStrong Sell Calls Recommendations For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) At 0 - Investor Newswire
06/24/16 02:18 PMPrice Target Update on Aegerion Pharmaceuticals (NASDAQ:AEGR) - Trade Calls
06/24/16 10:05 AMAegerion Pharmaceuticals Inc. (AEGR) Jumps 7.05% on June 23 - Equities.com
06/22/16 07:29 PMAegerion Pharmaceuticals Inc. (AEGR) Drops 5.56% on June 21 - Equities.com
06/21/16 02:18 PMUpdate in Lawsuit for Investors in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares announced by ... - Nasdaq
06/21/16 08:50 AMUpdate in Lawsuit for Investors in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) shares announced by Shareholders Foundation - [GlobeNewswire] - SAN DIEGO, June 21, 2016-- The Shareholders Foundation, Inc. announces that a lawsuit is pending in Massachusetts on behalf of certain purchasers of shares of Aegerion Pharmaceuticals, Inc. over alleged ...
06/19/16 07:05 AMStrong Buy Calls Count For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) At 1 - Investor Newswire
06/19/16 07:05 AMThis Weeks Broker Views For Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - Fiscal Standard
06/17/16 10:15 AMRatings Analysis of: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) - News Oracle
06/17/16 10:15 AMAegerion Pharmaceuticals Inc. (AEGR) is Trading Higher on Unusual Volume for June 15 - Equities.com

Social

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals logoAegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AEGR
  • CUSIP: 00767E10
Key Metrics:
  • Previous Close: $1.47
  • 50 Day Moving Average: $1.53
  • 200 Day Moving Average: $3.61
  • P/E Ratio: N/A
  • P/E Growth: -0.03
  • Market Cap: $42.48M
  • Beta: 0.59
  • Current Year EPS Consensus Estimate: $-3.03 EPS
  • Next Year EPS Consensus Estimate: $-0.86 EPS
Additional Links:
Aegerion Pharmaceuticals (NASDAQ:AEGR) Chart for Saturday, July, 30, 2016